Chunghwa Chemical Synthesis & Biotech Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 11, 2021
Share
Chunghwa Chemical Synthesis & Biotech Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 505.59 million compared to TWD 284.62 million a year ago. Net income was TWD 84.93 million compared to TWD 34.41 million a year ago. Basic earnings per share from continuing operations was TWD 1.09 compared to TWD 0.44 a year ago. Diluted earnings per share from continuing operations was TWD 1.09 compared to TWD 0.44 a year ago. Basic earnings per share was TWD 1.09 compared to TWD 0.44 a year ago. Diluted earnings per share was TWD 1.09 compared to TWD 0.44 a year ago.
For the nine months, sales was TWD 1,427.03 million compared to TWD 983.98 million a year ago. Net income was TWD 309.5 million compared to TWD 433.32 million a year ago. Basic earnings per share from continuing operations was TWD 3.99 compared to TWD 5.59 a year ago. Diluted earnings per share from continuing operations was TWD 3.96 compared to TWD 5.56 a year ago. Basic earnings per share was TWD 3.99 compared to TWD 5.59 a year ago. Diluted earnings per share was TWD 3.96 compared to TWD 5.56 a year ago.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.